Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations

Author:

Adhyaru Bhavin B.,Jacobson Terry A.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Reference37 articles.

1. • Robinson JG, Stone NJ. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur Heart J. 2015;36(31):2110–8. This article summarizes the 2013 ACC/AHA guidelines on lipid management and how it represents a paradigm shift from prior guidelines. It also introduces new evidence and the rationale for some of the controversies of the 2013 ACC/AHA guideline

2. • Adhyaru BB, Jacobson TA. New cholesterol guidelines for the management of atherosclerotic cardiovascular disease risk: a comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association recommendations for patient-centered management of dyslipidemia. Cardiol Clin. 2015;33(2):181–96. This article highlights some of the important differences in the NLA and ACC/AHA guidelines

3. •• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92–125. This ACC consensus document summarizes in detail the recommendations of the ACC based on new clinical trial evidence and highlights the role of LDL-C thresholds as well as special populations. Also, it gives advice on the use of the nonstatins, including ezetimibe, bile acid sequestrants, PCSK9 inhibitors, and niacin. In addition, it offers a pragmatic approach to lipid management, and gives guidance to clinicians when the evidence base is incomplete

4. Orringer CE, Morris PB. Consensus between the American College of Cardiology and the National Lipid Association on the use of non-statin therapy for atherosclerotic cardiovascular disease prevention. J Clin Lipidol. 2016;10(3):458–61.

5. • Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9(2):129–69. 2015 Part 1 Recommendations of the National Lipid Association after publication of the 2013 ACC/AHA Cholesterol Guidelines. Emphasizes the importantce of patient centered care, the use of LDL and Non-HDL-C goals and targets, the use of nonstatins in further reducing LDL-C and ASCVD risk, the importance of LDL-C monitoring to assess the adequacy of the response to therapy, adherence to therapy, and to provide a monitoring metric that both patients and providers understand

Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3